# Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

Source: https://onco.cc/trials/nct03964727/  
OnCo record `nct03964727` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sacituzumab govitecan in advanced solid tumours, run by Gilead Sciences, active and no longer recruiting.

## Summary

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors is a phase 2 interventional study registered as NCT03964727 by Gilead Sciences, with 227 participants enrolled, started 2019-10-15 and due to reach its primary completion in 2025-01-15. Interventions recorded: Sacituzumab Govitecan-hziy. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: TROPiCS-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03964727
- Phase: 2
- Setting: A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
- Sponsor: Gilead Sciences
- Enrolled: 227
- Outcomes: Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment: Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] 12.9% vs Cohort 1 Group 2: NSCLC (Adenocarcinoma) 5.9% vs Cohort 1 Group 3: NSCLC (SCC) 6.5% vs Cohort 2: HNSCC 16.3% vs Cohort 3: EC 26.8% vs Cohort 4: ES-SCLC 44.2%; Overall Survival (OS): Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] 14.26 months vs Cohort 1 Group 2: NSCLC (Adenocarcinoma) 11.02 months vs Cohort 1 Group 3: NSCLC (SCC) 7.29 months vs Cohort 2: HNSCC 8.97 months vs Cohort 3: EC 14.95 months vs Cohort 4: ES-SCLC 11.73 months

## Sources

- ClinicalTrials.gov NCT03964727: https://clinicaltrials.gov/study/NCT03964727

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct03964727.json